This story is about using drug repurposing method for TNBC Therapy
In this article, we have demonstrated that combination treatment with DNA-demethylating agent decitabine and synthetic glucocorticoid dexamethasone works synergistically to suppress tumor growth and distant metastasis in triple-negative breast cancer (TNBC), through three different pathways, including induction of miR-708 expression, reactivation of DNMT suppressed pathways, and suppression of metastatic promoting genes. Surprisingly, RNAseq analysis reveals that treatment with decitabine alone stimulates multiple metastatic promoting genes, such as MMPs, and IL1β, but this stimulation can be further suppressed by co-treatment with dexamethasone. For the therapeutic opportunity, using the combined regimen of decitabine and dexamethasone to treat TNBC patients is clinically significant. Currently, decitabine is under multiple clinical trials in treating TNBC patients, and our data reveal that combining dexamethasone may help to prevent undesired metastatic promoting effects caused by decitabine treatment.